Technology

59322 readers

5106 users here now

This is a most excellent place for technology news and articles.

Our Rules

Follow the lemmy.world rules.
Only tech related content.
Be excellent to each another!
Mod approved content bots can post up to 10 articles per day.
Threads asking for personal tech support may be deleted.
Politics threads may be removed.
No memes allowed as posts, OK to post as comments.
Only approved bots from the list below, to ask if your bot can be added please contact us.
Check for duplicates before posting, duplicates may be removed

Approved Bots

founded 1 year ago

MODERATORS

[email protected]

510

Pharmaceutical companies hiked the price of 775 drugs this year so far, including Ozempic and Mounjaro — exceeding the rate of inflation (arstechnica.com)

submitted 9 months ago by [email protected] to c/[email protected]

32 comments fedilink hide all child comments

Pharmaceutical companies hiked the price of 775 drugs this year so far, including Ozempic and Mounjaro — exceeding the rate of inflation::Meanwhile, Senate to consider subpoenas to force pharma CEOs testify on prices.

you are viewing a single comment's thread
view the rest of the comments

[–] [email protected] 1 points 9 months ago

I read through this article and the articles it linked to and wasn’t able to find a list of price increases, or even just the worst ones. The 4.5% increase is the most I saw and that’s barely more than inflation. The Reuters article they cited said that price increases during the pandemic were below inflation, so this kinda averages it out.

The Reuters article had this tidbit:

Truist analyst Robyn Karnauskas said in a note that Eli Lilly (LLY.N), opens new tab planned to lower the prices of its Humalog and Humulin insulins by 75.8% and 70% respectively on Dec. 30, and to raise the price of its popular diabetes drug Mounjaro by 4.5% on Jan. 1. These changes were not included in 3 Axis' data.

I’ll take a 4.5% price increase alongside a 70-75% price cut any day of the week. And I say that partly because much (most?) of the demand for Mounjaro is because it can be used off-label for weight loss and not for it as a drug to treat diabetes. I’m not saying weight loss drugs should be unaffordable, but it does seem reasonable to treat off-label weight loss drugs as a luxury.